Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q1 2026 · 10-Q
Revenue$983.54K$983.54K−13.4% vs Q1 2025 Net Income-$1.14M-$1.14MN/M vs Q1 2025 EPS Diluted-$0.04-$0.04N/M vs Q1 2025 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flow-$55,292N/M Margins · derivedGross margin29.0%+41.0 pt vs Q1 2025
Operating margin-113.6%−46.8 pt vs Q1 2025
Net margin-116.2%−47.1 pt vs Q1 2025
ended Mar 31, 2026 · filed May 15, 2026 · 45 d after period end